(Q33347646)

26 July 2017

title

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy (English)

1 reference

transitional cell carcinoma

26 July 2017

main subject

1 reference

1 reference

Oscar Juan

4

0 references

Pilar Garrido

object named as

Pilar Garrido

8

0 references

Joan Carles Galcerán

object named as

Joan Carles

2

0 references

author name string

Miquel Nogué-Aliguer

1

1 reference

26 July 2017

Antonio Arrivi

3

1 reference

26 July 2017

Lorenzo Alonso

5

1 reference

26 July 2017

Albert Font

6

1 reference

26 July 2017

Begoña Mellado

7

1 reference

26 July 2017

Alberto Sáenz

9

1 reference

26 July 2017

Spanish Cooperative Group

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

26 July 2017

number of pages

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

26 July 2017

volume

97

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

2180-2186

1 reference

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Carboplatin versus cisplatin in solid tumors: An analysis of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10990

7 January 2021

Identifiers

DOI

10.1002/CNCR.10990

1 reference

26 July 2017

1 reference